herβ

Anti-HER3/ERBB3 Antibody (4V862) is a Rabbit IgG monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (1P393) is a Mouse IgG1 monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2W239) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

Anti-HER3/ERBB3 Antibody (2Y512) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HER3/ERBB3.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.

Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Zanidatamab (ZW25) is a humanised bispecific monoclonal antibody that simultaneously targets two distinct HER2 epitopes located on ECD2 and ECD4, thereby enhancing receptor clustering and signaling blockade, Zanidatamab exhibits strong anti-tumour activity, supporting its application in HER2-positive cancer research and antibody-based therapeutic development.

Anbenitamab (KN-026) is a novel Fc-fused bispecific antibody targeting the human epidermal growth factor receptor 2 (HER2). It simultaneously binds to two non-overlapping extracellular domain epitopes of HER2 (domain IV, targeted by trastuzumab, and domain II, targeted by pertuzumab). This biparatopic binding mode induces superior receptor clustering and rapid degradation, leading to potent inhibition of downstream signaling pathways such as MAPK and PI3K. Anbenitamab demonstrates significant anti-tumor activity in HER2-positive or low-expressing breast, gastric, and gastroesophageal junction cancers, and effectively mediates antibody-dependent cellular cytotoxicity (ADCC).

Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.

Trastuzumab beta (ABP 980), a biosimilar to Trastuzumab, is a monoclonal antibody (McAb) that targets the human epidermal growth factor receptor 2 (HER2). It is utilized in the research of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer [1].

Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.

Gancotamab (MM-302) is a HER2-targeting polyethylene glycolated liposome that encapsulates adriamycin to facilitate delivery to HER2-overexpressing tumor cells while limiting exposure to non-target tissues, including the heart.Gancotamab has antitumor activity and may be used to study advanced HER2-positive breast cancer.

Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).

Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation and exhibiting antitumour activity.

Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer.

Coprelotamab (GB221) is a humanized IgG1 monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2/ERBB2), which effectively blocks receptor dimerization and downstream proliferative signaling by specifically binding to the HER2 extracellular domain IV. This antibody not only disrupts the malignant cell cycle but also possesses potent antibody-dependent cellular cytotoxicity (ADCC), enabling the precise elimination of HER2-overexpressing tumor lesions by recruiting immune effector cells.

Patritumab-MMAE , an Anti-ERBB3/HER3 Reference Antibody, is produced in CHO cells. This antibody comprises a heavy chain of type huIgG1 and a light chain of type hukappa, with a predicted molecular weight (MW) of 150 kDa.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ monoclonal antibody inhibitor that targets human or rat HER2.

Anti-ERBB1/EGFR/HER1 Antibody is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. It possesses a human IgG1 heavy chain and a human κ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-ERBB1/EGFR/HER1 Antibody (7A7) is a humanized antibody produced in CHO cells, specifically targeting ERBB1/EGFR/HER1. It features a muIgG1 heavy chain and an mκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. It inhibits Neuregulin-stimulated growth of cultured breast cancer cells and can be utilized in breast cancer research.

Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.